Cargando…
Improving HER2 testing reproducibility in HER2-low breast cancer
HER2 is a pillar biomarker in breast cancer, and it is assessed by immunohistochemistry (IHC) using a three-tier scoring system and reflex in situ hybridization (ISH) for IHC score 2+. Novel HER2-directed antibody-drug conjugates have demonstrated significant antitumor activity in breast cancers wit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771736/ https://www.ncbi.nlm.nih.gov/pubmed/36627898 http://dx.doi.org/10.20517/cdr.2022.29 |
_version_ | 1784854878147837952 |
---|---|
author | Sajjadi, Elham Venetis, Konstantinos Ivanova, Mariia Fusco, Nicola |
author_facet | Sajjadi, Elham Venetis, Konstantinos Ivanova, Mariia Fusco, Nicola |
author_sort | Sajjadi, Elham |
collection | PubMed |
description | HER2 is a pillar biomarker in breast cancer, and it is assessed by immunohistochemistry (IHC) using a three-tier scoring system and reflex in situ hybridization (ISH) for IHC score 2+. Novel HER2-directed antibody-drug conjugates have demonstrated significant antitumor activity in breast cancers with low levels of HER2 expression, i.e. IHC score 1+ or ISH-negative IHC score 2+. Both primary and acquired resistance to anti-HER2 therapies remains a challenge in the treatment of breast cancers according to the HER2 positivity continuum. Thus, the ability to precisely discriminate among HER2-zero, HER2-low, and HER2-positive breast cancers is no longer a mere academic exercise. HER2 testing criteria, guidelines, and quality controls are re-gaining momentum for this new clinical need. Therefore, all preanalytical and analytical variables that might trouble the sensitivity and reproducibility of this test should be carefully considered to address all possible issues and open all possible therapeutic opportunities for breast cancer patients. |
format | Online Article Text |
id | pubmed-9771736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | OAE Publishing Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97717362023-01-09 Improving HER2 testing reproducibility in HER2-low breast cancer Sajjadi, Elham Venetis, Konstantinos Ivanova, Mariia Fusco, Nicola Cancer Drug Resist Opinion HER2 is a pillar biomarker in breast cancer, and it is assessed by immunohistochemistry (IHC) using a three-tier scoring system and reflex in situ hybridization (ISH) for IHC score 2+. Novel HER2-directed antibody-drug conjugates have demonstrated significant antitumor activity in breast cancers with low levels of HER2 expression, i.e. IHC score 1+ or ISH-negative IHC score 2+. Both primary and acquired resistance to anti-HER2 therapies remains a challenge in the treatment of breast cancers according to the HER2 positivity continuum. Thus, the ability to precisely discriminate among HER2-zero, HER2-low, and HER2-positive breast cancers is no longer a mere academic exercise. HER2 testing criteria, guidelines, and quality controls are re-gaining momentum for this new clinical need. Therefore, all preanalytical and analytical variables that might trouble the sensitivity and reproducibility of this test should be carefully considered to address all possible issues and open all possible therapeutic opportunities for breast cancer patients. OAE Publishing Inc. 2022-09-01 /pmc/articles/PMC9771736/ /pubmed/36627898 http://dx.doi.org/10.20517/cdr.2022.29 Text en © The Author(s) 2022. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Opinion Sajjadi, Elham Venetis, Konstantinos Ivanova, Mariia Fusco, Nicola Improving HER2 testing reproducibility in HER2-low breast cancer |
title | Improving HER2 testing reproducibility in HER2-low breast cancer |
title_full | Improving HER2 testing reproducibility in HER2-low breast cancer |
title_fullStr | Improving HER2 testing reproducibility in HER2-low breast cancer |
title_full_unstemmed | Improving HER2 testing reproducibility in HER2-low breast cancer |
title_short | Improving HER2 testing reproducibility in HER2-low breast cancer |
title_sort | improving her2 testing reproducibility in her2-low breast cancer |
topic | Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771736/ https://www.ncbi.nlm.nih.gov/pubmed/36627898 http://dx.doi.org/10.20517/cdr.2022.29 |
work_keys_str_mv | AT sajjadielham improvingher2testingreproducibilityinher2lowbreastcancer AT venetiskonstantinos improvingher2testingreproducibilityinher2lowbreastcancer AT ivanovamariia improvingher2testingreproducibilityinher2lowbreastcancer AT fusconicola improvingher2testingreproducibilityinher2lowbreastcancer |